Quinn Opportunity Partners LLC Janux Therapeutics, Inc. Transaction History
Quinn Opportunity Partners LLC
- $1.08 Billion
- Q2 2025
A detailed history of Quinn Opportunity Partners LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Quinn Opportunity Partners LLC holds 59,893 shares of JANX stock, worth $1.71 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
59,893
Previous 51,893
15.42%
Holding current value
$1.71 Million
Previous $1.4 Million
1.28%
% of portfolio
0.13%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
187Shares Held
56MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$319 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$127 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$83.3 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$72 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$66.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.19B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...